BRCA1, BRCA2 and a subset of Fanconi's Anaemia proteins act to promote RAD51-mediated protection of newly 10 synthesised DNA at stalled replication forks from degradation by nucleases. How BRCA1 contributes, how it is 11 regulated and whether replication fork protection relates to, or differs from, the roles BRCA1 has in homologous 12 recombination is not clear. Here we show that the canonical BRCA1-PALB2 interaction is not required for fork 13
Introduction. 23
Genomic integrity is constantly under threat by problems that the replication fork might encounter 1 . Fork 24 progression can be slowed by conflicts with transcription, deoxyribonucleotide (dNTP) shortage or difficult to 25 replicate sequences, frequently causing fork stalling. To avoid replication stress, a set of responses act to prevent 26 replication forks from collapsing, amongst which is fork remodelling and subsequent nascent strand protection. 27
In remodelling newly made DNA strands anneal and a four-way, chicken foot structure is evident in electron 28 microscopy (also called nascent strand exchange or fork reversal 2,3 ). Agents that cause replicative stress or 29
compromise Pol alpha function result in a proportion of forks reversing 2-5 , reviewed in 6,7 . The regressed arm of 30 nascent DNA in reversed forks resembles a single-ended DNA double strand break, and while some resection of the 31 structure is required for replication fork restart, the reversed fork is protected from excessive resection by RAD51. 32 Several factors contribute to RAD51-mediated fork protection including BRCA1/2, FANCA/D2, RAD51 paralogs, 33 BOD1L, SETD1A WRNIP and Abro1 [8] [9] [10] [11] [12] [13] [14] . 34
An emerging theme is that stability of the RAD51-nucleofilament is critical to the protection of stalled forks 8, 15 . 35 Increased dissociation of RAD51 mutants compromises their ability to prevent fork degradation [16] [17] [18] . Also, factors 36 such as BOD1L stabilise RAD51 on ssDNA and promote fork protection 19 , while others, such as RADX, compete with 37 or dissociate RAD51, so that their depletion rescues fork protection of BRCA-defective cells 20, 21 . 38
Failure of replication fork protection is associated with genome instability, but whether it constitutes a distinct 39 tumour suppressor pathway is not yet clear. Restoration of replication fork protection in BRCA-deficient cells is 40 linked to chemotherapy resistance in some cell types and contexts [22] [23] [24] . Thus further mechanistic understanding of 41 fork protection is thus needed to inform cancer patient care. 42 BRCA1 is found at ongoing and stalled replication forks [25] [26] [27] and like BRCA2, contributes to RAD51-mediated defence 43 of stalled forks from MRE11-dependent degradation 9 . Cells with BRCA1 haplo-insufficiency show more frequently 44 degraded forks 28 , suggesting that poor fork degradation may allow genome instability in the normal and pre-45 cancerous cells of BRCA1 mutation carriers. However, how BRCA1 contributes to fork protection is not clear. 46
The data presented here reveal BRCA1 promotes the protection of nascent DNA at stalled replication forks 47
independently of the canonical BRCA1-PALB2 interaction. Instead we find that an enhanced direct interaction 48 between BRCA1-BARD1 and RAD51 is required for fork protection and that this enhanced interaction is dependent 49 on conformational changes catalysed by the phosphorylation directed prolyl isomerase, PIN1. These newly 50 identified BRCA1 and BARD1 regions required for fork protection harbour patient variants associated with familial 51
and sporadic cancer which can inhibit fork protection. Additionally our data infers that the enhanced RAD51-52 BARD1-BRCA1 interaction stabilises RAD51-synapse-like structures at stalled forks. 53 54
Results. 55
The BRCA1-BARD1 heterodimer promotes fork protection through the RAD51 binding region and not the PALB2-56 BRCA2 interaction region. 57
During homologous recombination (HR) of DNA double-strand breaks (dsDNA breaks), BRCA1-BARD1 regulates 58 RAD51 localisation and loading through PALB2-BRCA2 29-31 and also directly interacts with RAD51 to promote 59 invasion and D-loop formation 32 . BRCA1, PALB2 and BRCA2 are found at stalled and collapsed replication forks 33 60 and while the PALB2-BRCA2 interaction is required for fork protection 34 , it is unclear whether the BRCA1-PALB2 61 interaction is relevant. To address this question we examined nascent DNA at hydroxyurea (HU) stalled forks. Newly 62 synthesized DNA was labelled using CldU before stalling with 5 mM HU for 3 hours. After DNA fibre-spreading, the 63 length of the label was measured as an indicator of the stability of newly synthesized DNA at stalled replication 64 forks 8 9 ( Fig 1A) . Replication stalling caused a dramatic shortening of CldU tract lengths in BRCA1 or PALB2 depleted 65 cells (just 8.6 and 8.7 m respectively in PALB2 and BRCA1 depleted cells compared to 13.7 m in controls) ( Fig 1B-66 C). BRCA1 and PALB2 directly interact through coiled-coil motifs 30, 31 . The BRCA1-M1141T point mutation prevents 67 the PALB2 interaction, fails to support HR-repair 31 , and shows increased sensitivity to the inter-strand cross-linker 68
Cisplatin in colony survival assays ( Supplementary Fig 1A-C) . Similarly, an N-terminal coiled-coil deletion mutant of 69 PALB2 (ΔNT-PALB2) fails to interact with BRCA1 30,31 and shows increased sensitivity to Cisplatin in colony survival 70 assays ( Supplementary Fig 1D) . Surprisingly, when we used these interaction mutants to assess fork protection 71 using the CldU incorporation assay, both BRCA1-M114T and ΔNT-PALB2 were able to stabilise stalled replication 72 fork tract lengths in BRCA1 or PALB2 siRNA-depleted cells to similar lengths as controls ( Fig 1D-G) . In contrast to 73 this, the BRCA1-PALB2 canonical interaction is required for replication after HU incubation as both the M1411T-74 BRCA1 and NT-PALB2 mutations exhibit a reduced proportion of replication fork restart and increased fork stalling 75
( Supplementary Fig 1E-H) . Therefore, while both BRCA1 and PALB2 are required to protect nascent DNA at stalled 76 replications forks, fork restart, but not fork protection, is dependent on the canonical interaction between BRCA1 77 and PALB2. 78
Both BRCA1 and BARD1 carry regions able to directly interact with RAD51 32,35 . BARD1 residues F133, D135 and 79 A136 form part of an interaction face with RAD51, and are required for D-loop formation in HR and for mitomycin C, 80
Olaparib and HU resistance 32 ( Supplementary Fig 1I-J) . We assessed cells complemented with BARD1 bearing 81 substitutions in this RAD51-binding site (F133A-D135A-A136E, termed AAE-BARD1). Depletion of BARD1 caused a 82 similar decrease in CldU tract lengths as that seen following BRCA1 depletion (11.4 µm in controls vs 6.5 µm in 83 siBARD1) after HU treatment and complementation with WT-BARD1 but not AAE-BARD1 supported protection of 84 nascent strands (11.1 µm vs 6.3 µm) ( Fig 1H-I) . In contrast when we assessed the requirement for the BRCA1-BARD1 85 E3 ubiquitin ligase function we found that complementation with R99E-BARD1, a mutant that specifically disrupts 86 E3 ligase activity without disrupting the BRCA1-BARD1 heterodimer 36 , was sufficient to restore longer CldU tract 87 lengths following HU-induced fork stalling (9.6 µm Vs 8.7 µm in cells with WT-BARD1) ( Fig 1J-K) . Therefore, 88 protection of stalled replication forks requires a functional RAD51 binding site in BARD1 but not the BRCA1-BARD1 89 E3 ubiquitin ligase activity, nor the canonical BRCA1-PALB2 interaction. 90
91
The BRCA1 serine 114 phosphorylation site is required for the protection of nascent DNA. 92 BRCA1 and BARD1 are phosphorylated at residues that are structurally potentially close to the BARD1-RAD51 93
interaction site: at S148 in BARD1 37 and S114 in BRCA1 38, 39 . We tested whether these sites are required in fork 94 protection by mutation and found substitution to alanines (S114A-BRCA1 or S148A-BARD1) shortened CldU tract 95 lengths following HU-treatment but not in the absence of HU-treatment ( Fig 2A-B and Supplementary Fig 2A-C) . In 96 contrast, mutation to aspartate (D) as a phospho-mimic was able to support fork protection in S114D-BRCA1 97 complemented cells but not in S148D-BARD1 complemented cells (Fig 2C-D and Supplementary Fig 2D-E),  98 supporting a role for BRCA1 phosphorylation in fork protection. 99
The S114A-BRCA1 and WT-BRCA1 had similar levels of recruitment to sites of active replication identified by the 100 incorporation of the nucleotide analogue CldU following a pulse treatment ( Supplementary Fig. 2F ) and both 101 mutant and WT-BRCA1 interacted with BARD1 to the same degree ( Supplementary Fig 2G) . 102 BRCA1 has several roles at replication forks 40 and depletion of BRCA1 increased the stalling of ongoing replication 103 and also reduced replication restart following release from short term (3 hour) exposure to 5 mM HU. 104
Complementation with either WT-BRCA1 or S114A-BRCA1 restored both ongoing forks and fork restart ( Fig 2E-F ) 105
suggesting that the S114-site is not significant to these aspects of replication stress. Fork protection defects can be 106 restored in BRCA1/2 deficient cells by inhibition of MRE11 3'-5' nuclease activity with Mirin 9 , and similarly Mirin 107 restored long tract lengths in S114A-BRCA1 complemented cells (from 7.6 m to 11.3 m) ( Supplementary Fig 2H-108 1), implicating the S114-site in the protection of nascent DNA from nuclease activity. 109 110
Phosphorylation of BRCA1 at serine 114 promotes PIN1 interaction. 111
We generated an antibody to a phosphorylated-S114 BRCA1 peptide (p-S114) which was able to detect 112 immunoprecipitated WT-BRCA1 and not S114A-BRCA1 ( Fig 3A) , confirming phosphorylation at S114. Intriguingly, 113 the BRCA1 phospho-S114 site lies within an S-P motif which is a minimal consensus site for the phospho-peptidyl-114 prolyl isomerase (PPIase), PIN1, and BRCA1 and BARD1 have previously been enriched from lysates using 115 recombinant PIN1 41 . We were able to confirm their interaction by immunoprecipitation of the BARD1-BRCA1-PIN1 116 complex from cells over-expressing RFP-Flag-BARD1 ( Fig 3B) . Since protein interactions with the full length PIN1 117 enzyme are transient, we generated a GST-fusion of the PIN1 WW phospho-binding domain (GST-WW) without the 118
PPIase domain, and a corresponding GST-W34A mutant form which is deficient in phospho-binding, to explore PIN1 119 interactions further 42 ( Supplementary Fig 3A) . Purification of WT-BRCA1 and the S114D-BRCA1 phospho-mimic, but 120 not S114A-BRCA1 was achieved by GST-WW, but not GST-W34A ( Fig. 3C and Supplementary Fig 3B) . Furthermore, 121 the interaction between either exogenous Flag-EGFP-BRCA1 or endogenous BRCA1 and recombinant PIN1-WW 122 domain was increased following HU treatment ( Fig 3D and Supplementary Fig 3C) . The interaction of endogenous 123 BRCA1 with PIN1-WW domain was lost following treatment of the cell lysate with phosphatase ( Supplementary Fig  124  3C , final lane). In contrast, while WT-BARD1 was also purified by GST-WW and not GST-W34A, this interaction was 125 not lost on mutation of the RAD51 proximal phosphorylation site S148 (S148A-BARD1) ( Supplementary Fig 3D)  126 suggesting that pS148-BARD1 is not a PIN1 interaction site. Together these data suggest that BRCA1 is 127 phosphorylated at S114 in response to HU and that this phosphorylation promotes the ability of the PIN1-WW 128 domain to purify BRCA1. 129
The BRCA1 S114 site lies within a loose CDK1/2 consensus site (S-P-x-x-x-K) and treatment of cells with the CDK1/2 130 inhibitor (Roscovitine), the CDK1 inhibitor (RO-3306) or with CDK1 siRNA reduced the affinity of the p-S114 antibody 131
for immunoprecipitated BRCA1 and the ability of the GST-WW domain of PIN1 to purify BRCA1 from cell lysates ( Fig  132  3E and Supplementary Fig 3E-F) . Similarly incubation of recombinant CDK2/Cyclin A with recombinant WT or S114A 133
His-BRCA11-300-BARD126-142 specifically phosphorylated WT-BRCA1 but not S114A-BRCA1 ( Supplementary Fig 3G) . 134
These data indicate CDK-mediated phosphorylation at S114 contributes to the ability of PIN1 to interact with 135 BRCA1. 136 137 PIN1 regulates the BRCA1-BARD1 heterodimer to promote fork protection. 138 PIN1 is expressed at low levels in non-proliferating cells and increases with proliferative capacity (reviewed in 43 ) and 139 studies that have isolated proteins on nascent DNA (iPOND) have shown PIN1 enrichment following treatment with 140 HU 20,25,44 . Inhibition of PIN1 with Juglone, or depletion of PIN1 by siRNA, led to a shortening of CldU tracts following 141 HU-treatment consistent with a fork protection defect. This was epistatic with BRCA1 or BARD1 loss ( Fig 4A-B and 142
Supplementary Fig 4A-C) suggesting that PIN1's role in fork protection lies in the same pathway as BRCA1-BARD1. 143
While a common outcome of PIN1 interaction is altered protein stability 41,45-48 , we saw no gross impact on BRCA1 144 or BARD1 levels following PIN1 depletion ( Fig 4B and Supplementary Fig 4C) . 145
In folded proteins, peptide bonds preceding residues other than proline (non-prolyl bonds) overwhelmingly favour 146 the trans form, and cis bonds are rare in folded proteins 49 . In contrast, due to the physical constraints of proline's 147
unique 5-membered ring on the peptide backbone, peptide bonds preceding proline (prolyl bonds) more often 148 adopt the cis conformation 50 . PIN1 is the only phospho-targeted PPIase; it specifically recognises phospho-S/T-P 149 motifs 51 before catalysing a cis-trans conformational change on the peptidyl-prolyl bond in the peptide backbone 52-150 57 . An experimental approach often used to examine potential requirements for the trans-isomer is to substitute the 151 proline of the target with other amino acids 58,59 . We tested the requirement for proline isomerisation to trans by 152 mutating BRCA1 P115 to an alanine to constitutively present a trans backbone prior to residue 115 ( Fig 4C) . 153 P115A-BRCA1 was able to complement BRCA1 depletion preventing shortening of nascent tracts after HU exposure, 154
suggesting no negative impact of trans-isomerisation or proline loss at this position ( Fig 4D-E) . Importantly inclusion 155 of P115A with the S114A mutation resulted in normal CldU tract lengths in BRCA1-depleted cells ( Fig 4D) , showing 156 that inclusion of an alanine at P115 can overcome the requirement for serine at 114. These data suggest trans 157 isomerisation of P115 bypasses the need for S114 phosphorylation. In addition, mutation of P115 to another amino 158 acid, cysteine, also overcame the requirement for the S114-site in fork protection ( Supplementary Fig 4D- 
supporting the hypothesis that this is due to presenting BRCA1 in a trans conformation at position 115 rather than 160 due to a specific effect of alanine at P115. 161
We next addressed the degree to which the failure to maintain nascent DNA in cells with repressed PIN1 is due to 162 isomerisation at P115-BRCA1. In BRCA1 and PIN1 co-depleted cells expression of P115A or S114A-P115A-BRCA1 163 resulted in lengthened average tract lengths (11.0 m in P115A and 11.7m in S114A-P115A cells) compared to 164 cells with BRCA1+PIN1 co-depletion (8.3 m). However, lengths were not fully restored to that of nascent strands in 165 control cells (12.9 m) ( Fig. 4F-G) . Thus the requirement for PIN1 in replication fork protection can be largely 166 overcome by expression of a trans-locked mutant of BRCA1 at position P115, suggesting the majority of the need 167
for the PIN1 PPIase is through BRCA1. 168 169 BRCA1-BARD1 isomerisation enhances direct RAD51 binding and promotes accumulation at nascent DNA. 170
Using recombinant purified His-BRCA11-500-BARD127-327 ( Supplementary Fig 5A) we used limited trypsin proteolysis to 171 assess the cis-trans conformational change predicted by mutation of P115 to alanine. The P115A version of BRCA1 172 was more resistant to trypsin, transitioned more slowly through the ~18 kDa intermediate at 3-15 minutes post 173 addition of trypsin, and formed the ~15 kDa fragment maximally at 30 min post-trypsin compared to 3 minutes with 174
WT-BRCA1. The same size kDa fragments are formed by both WT and P115A suggesting that there is no gross 175 change of domain structure but rather a change in accessibility to the same trypsin digestion sites ( Fig 5A) . These 176
data are consistent with a subtle structural conformational difference between WT and P115A-BRCA1. Given the 177 potential proximity of P115 in BRCA1 to the RAD51 binding site of BARD1 we next asked whether cis-trans 178 isomerisation of BRCA1 would affect RAD51 binding to the BRCA1-BARD1 heterodimer. WT and P115A recombinant 179
His-BRCA11-500-BARD127-327 were incubated with active recombinant RAD51 and the direct protein-protein 180
interaction assessed by His-pull down. Our analysis, demonstrated greater recombinant RAD51 binding to the trans 181 P115A BRCA1-BARD1 heterodimer compared to the WT-BRCA1-BARD1 heterodimer ( Fig 5B) . 182
We then wanted to address the BRCA1-BARD1-RAD51 interaction in cell lysates. Immunoprecipitation of P115A-183 BRCA1 in complex with WT-BARD1 showed a 1.5-fold enhancement in the interaction with RAD51 compared to WT-184 BRCA1 ( Fig 5C and Supplementary Fig 5B) . To assess any influence on RAD51 at nascent DNA following HU-185 treatment we used proximity linked ligation assay (PLA) with antibodies to RAD51 and Biotin conjugated to EdU 60 . 186
This showed that BRCA1-depleted cells complemented with S114A-P115A-BRCA1 showed RAD51 PLA foci levels 187 similar to WT complementation and greater than the S114A-BRCA1 complementation or BRCA1 depleted cells ( Fig  188  5D and Supplementary Fig 5C) . Thus a trans-locked form of BRCA1 at the peptidyl-115 bond overcomes the 189 requirement for a functional phosphorylation site at S114 in promoting RAD51 accumulation at nascent DNA. 190 Likewise in cells depleted for BRCA1 and PIN1 the RAD51 PLA foci levels were restored by complementation of 191 S114A-P115A-but not S114A-BRCA1 ( Fig 5E) . These data indicate that isomerisation of BRCA1 contributes to the 192 presence of RAD51 at stalled forks. 193
194

Loss of BRCA1-isomerisation leads to genomic instability and increased sensitivity to replication stress agents. 195
Mutation of the RAD51 binding site in BARD1 (AAE) leads to increased sensitivity to both replication stress (HU) and 196 DNA damaging agents such as Olaparib and Camptothecin that require HR-directed repair 32 ( Supplementary Fig  197  1I&J ). When we assessed the requirement of the S114-site in BRCA1 for cell survival in response to PARP inhibitors 198 (Olaparib, Veliparib or 4AN) or replication stress agents (HU or Aphidicolin) we found complemented cells were 199 resistant to PARP inhibitors and formed RAD51 foci after Olaparib treatment but were sensitive to overnight 200 treatment with replication stress-inducing agents ( Supplementary Fig 6A- C, Fig 6A-B ). Since prolonged treatment 201 with HU causes replication fork collapse and the formation of double strand breaks, we also assessed colony 202 survival in response to conditions that promote fork stalling but not collapse (3 hour treatment of 5 mM HU) 61 , 203
conditions identical to those used in our fork protection assays. Intriguingly, even in asynchronous cells treated with 204 short-term HU, the S114A-BRCA1 complemented cells showed reduced colony formation ( Fig 6D) . Moreover 205
inclusion of the P115A mutation on the S114A background was sufficient to rescue the S114A defect in survival seen 206 in response to both 3 hour and overnight treatment with HU ( Fig 6D-F) . In previous reports low-dose HU 207 experiments have had little-impact on cell survival (for example of BRCA2-deficeint cells 9 ). We have discounted 208 several replication defects (restart, fork speed, stalling) and in our hands resistance to both short and long-term HU 209 exposure closely correlates with fork protection. 210
These data lead us to investigate the role of the phosphorylation-isomerisation region of BRCA1 in genome stability. 211
As expected depletion of BRCA1 increased both the average number of breaks per metaphase (from 3.4 in controls 212 to 6.5 in BRCA1-depleted cells) and the percentage of metaphases with chromatid exchanges (10.3 % in controls to 213 40.4 % in siBRCA1) ( Fig 6G-I) . Strikingly, cells complemented with WT-BRCA1 or S114A-P115A-BRCA1 double 214 mutant, but not S114A-BRCA1, were able to restore the average number of breaks per metaphase to levels seen in 215 controls ( Fig 6G-H) . In contrast, complementation with the mutants restored the percentage of chromatid 216 exchanges to control and WT-BRCA1 levels ( Fig 6G & I) . 217
Taken together the S114-P115 region contributes support to nascent DNA protection, the prevention of 218 chromosome breakage and HU resistance. The data are consistent with a model in which trans-BRCA1 promotes 219
replication fork protection thereby preventing DNA breaks and cell death following replication stress. Radials are 220 also associated with short-term HU treatment in cells lacking BRCA2 or RAD51-paralogs 8,62 . They are a result of 221 illegitimate recombination, and may represent toxic-NHEJ of cells deficient in HR-repair 63 . We find they correlate 222
with proficient response to Olaparib and are not associated with the fork protection defect associated with the 223 phosphorylation-isomerisation region of BRCA1. 224
225
Patient variants define novel functional regions of BRCA1-BARD1 required for fork protection. 226
Our data are surprising in having established a region of BRCA1 required for the protection of replication forks and 227 the prevention of replication-stress mediated genome instability and cell death that has no role in PARPi sensitivity 228
and shows no features of promoting HR. We were therefore interested to know if genetic changes identified in 229 patients with a family or personal history of breast or ovarian cancer generate mutant BRCA1 protein with similar 230
features. The Breast cancer information core, cBioportal and literature shows genetic variants that alter the coding 231 sequence within or close to the BRCA1 S114-P115 phosphorylation-isomerisation site and the BARD1-RAD51 232 binding site (https://research.nhgri.nih.gov/bic/ 64,65 66 ). We generated point mutations corresponding to those that 233 introduce amino acid changes with high Grantham difference and low variance (i.e are chemically highly distinct 234 from the reference residue and occur in a residue highly conserved across species) 67 ( Fig 7A-B ). BRCA1 patient 235 variants, S114P, R133C, Y179C, S184C, S256Y showed shorter CldU tract lengths consistent with a fork protection 236 defect ( Fig 7C-G) . BARD1 patient variants located in the RAD51 binding domain of BARD1, with the exception of 237 D135Y, also showed shorter CldU tract lengths compared to controls ( Fig 7H-I) . Moreover all mutants that showed a 238 fork protection defect, also showed increased sensitivity to HU, but not to Olaparib, in colony survival assays (Fig 7J-239 M and Supplementary Fig 7A-D) . Intriguingly Y101N-BRCA1, which is proficient for fork protection and shows HU 240 resistance, is sensitive to PARPi, demonstrating functional separation in the other direction ( Fig 7E, G, L and 241 Supplementary Fig 7C) . These data confirm the identification of novel regions of the heterodimer, mutated in 242 cancers, that are required for fork protection and response to replicative stress that do not promote cellular 243 responses to PARP-inhibitor, Olaparib. 244 245
Discussion. 246
Our study reveals that CDK-PIN1 regulated conformational change in BRCA1 results in a new interface between 247 BRCA1-BARD1 and RAD51 to promote fork protection. While PIN1 activity is capable of disrupting dimers and 248 aggregates 68 69 and of driving interactions specific for cis or trans conformations (reviewed in 70 ), the mechanism we 249 identify here, that of isomerisation on one partner of a heterodimer, driving improved protein:protein interaction 250 largely mediated by the other heterodimer partner, appears unique. We do not rule out the creation of new 251 contacts on both BRCA1 and BARD1, indeed the cancer-associated patient mutations we identify extend the regions 252 of both proteins involved in fork protection. We speculate these mutations represent sensitivities of a new domain 253 structure brought about by proline isomerisation at BRCA1-P115. 254
In addition we reveal post-translational modifications induced by HU-treatment are required for fork protection. 255
The CDK-PIN1 regulation of BRCA1 dove-tails with that of BRCA2 regulation in which CDK2-mediated 256 phosphorylation of BRCA2, which would inhibit its binding to RAD51, is actively repressed in S-phase by ATR 257 signalling and the components of the core Hippo pathway 71,72 . 258
Our findings build on the view that a greater stability of RAD51-ssDNA is needed for fork protection. We show trans 259 BRCA1-BARD1 specifically increases the degree of direct RAD51 binding. Since BRCA1 fork protection and fork 260 restart processes are not coupled (Fig2A & F), whether the stability provided by BRCA1-BARD1-RAD51 interaction is 261 relevant to this process remains to be investigated. 262
The separation of function mutation at BRCA1-S114A, is particular in exhibiting a fork protection defect but having 263 no measurable impact on fork stalling, fork restart or HR and thus in examining chromosome aberrations we 264 identify a close correlation between poor fork protection and chromosomal breaks. How breaks occur is not clear 265 but they may arise from the processing of stalled, de-protected structures to allow cells to survive into mitosis (eg 266 73 ). We expect that our analysis of metaphases after short-term HU under-represents chromosome damage since 267 unprotected forks can also be converted into anaphase bridges and subsequently broken later in mitosis 19, 74 . 268
Our data reveals a direct function for BRCA1 in fork protection that is separate from the canonical PALB2-BRCA2 269 recruitment, leaving the question of how PALB2 and BRCA2 are recruited to stalled forks? In this context it may be 270 relevant that PALB2 can be recruited through RNF168 or phosphorylated RPA at DNA double-strand breaks and 271
both are present at stalled replication forks 75-77 . 272
Such an elaborate mechanism of BRCA1-BARD1 regulation, specific to fork protection, also raises the question of 273 why RAD51 interaction is so exquisitely regulated. One possibility is that excessive RAD51 can be deleterious. 274
Indeed excessive RAD51 at replication forks results in fork collapse in unperturbed replication 20,78,79 and breast and 275 lung cancer patients with high levels of RAD51 tend to do poorly compared to patients with lower levels 12 . 276
We report eight patient-derived variants in BRCA1-BARD1 that impair fork protection, but not HR. These include a 277 germline patient variant corresponding to the S114 phosphorylation site, BRCA1 T459Ca,c (pS114P) in BRCA1 exon 7 278 from a 35 year old patient from northern India with stage II, lymph node positive familial breast cancer 66 . The 279 impact of these mutants implies a wider role for fork protection in cancer development than previously 280 described 16, 17 . Whether other regions of BRCA1-BARD1 are also specifically required for fork protection, and 281 whether loss of fork protection is sufficient to result in cancer predisposition requires further investigation. 282 PIN1 is amplified or highly expressed in ~15% of common cancers 80-82 ). It has not previously been implicated in 283 endogenous mammalian DNA replication, although indirectly elevated expression is likely to increase replicative 284 stress through oncogene activation and the induction of a shortened G1 phase 83-89 . Its up-regulation acts to 285 potentiate the function of several oncogenic pathways driving cell cycle progression and cell proliferation 43,85,90-93 . 286
Several PIN1 small molecule antagonists and peptide inhibitors have been described (reviewed in 94 ). Recently all-287 trans retinoic acid, used in the treatment of acute promyelocytic leukemia, was found to result in PIN1 degradation 288
and thus the application of the drug a to wider cancer repertoire suggested 95, 96 . Our finding that PIN1 is required 289 for replication fork protection reveals a new cross-talk pathway that may bring opportunities in cancer therapies, 290 potentially improving the efficacy of replication stressing or immune-checkpoint therapeutics by increasing 291 cytotoxicity and mutagenic load. plates and kept at 5% CO2 and 37°C. Once cells reached 70-80% confluency they were passaged. Cells were tested 300
for Mycoplasma by Hoescht staining. 301
Inducible stable cell line generation 302
Flp-In TM HeLa, U20S and HEK293 cells were plated in 10 cm 2 dishes and transfected with a mixture containing the 303 gene of interest cDNA in the pcDNA5/FRT/TO vector and the Flp recombinase cDNA in the pOG44 vector. Control 304 transfections were carried out without the pOG44 recombinase. Two days after transfection, cells were preselected 305 with 100 μg/ml Hygromycin, cell culture medium was replaced every 2-3 days and cells were selected for 306 approximately 2 weeks. After selection cells were expanded and tested for expression of Flag-EGFP-BRCA1, RFP-307
Flag-BARD1 or Flag-PALB2. Cells were treated with 2 μg/ml Doxycycline for 24, 48 and 72 hours and expression 308 levels were checked by western blotting. 309
Plasmid and siRNA transfection 310
FuGENE 6 (Roche) was used as a reagent to transfect DNA plasmids into cells, the ratio used was 3:1 FuGENE (μl): 311 DNA (μg), following the manufacturer's guidelines. siRNA transfections were carried out using the transfection 312 reagent Dharmafect1 (Dharmacon) following the manufacturer's instructions. For a full list of siRNA sequences see 313 Supplementary Table 1 . 314
Colony survival assays 315
Flp-In TM U20S or Hela cells were plated in 24 well plates at 4 x 10 4 cells/ml and treated according to the experiment 316 performed. Cells were trypsinised in 100 μl of 1x Trypsin and resuspended in 900 μl of PBS. Cells were plated out at 317 limiting dilutions and incubated for a further 10-14 days at 37 °C at 5 % CO2. Once colonies had grown they were 318 stained with 0.5 % Crystal violet in 50 % methanol and counted. 319
Metaphase spreads 320
Flp-In TM U20S cells were treated with 5 mM HU for 4 hours and then incubated with Colcemid (0.05 µg/ml) 16 321 hours. Cells were trypsinized and centrifuged at 1200 rpm for 5 minutes. Supernatant was discarded and cells 322 resuspended in PBS. 5 ml of ice-cold 0.56 % KCl solution was added and incubated at room temperature for 15 min 323 before centrifuging at 1200 rpm for 5 min. Supernatant was discarded and cell pellet broken before fixation. Cells 324 were then fixed in 5 ml of ice-cold methanol: glacial acetic acid (3:1). Fixation agents were removed and 10 μl of cell 325 suspension was dropped onto alcohol cleaned slide. Slides were allowed to dry at least 24 hours and then stained 326
with Giemsa solution (Sigma) diluted 1:20 for 20 min. Slide mounting was performed with Eukitt (Sigma). 327
Proximity Ligation Assay 328
Flp-In TM U20S cells were seeded at a 4 x 10 4 cells/ ml confluence onto poly-L-lysine coated coverslips and EdU 329 pulsed for 10 minutes at 37°C for 10 minutes. 5 mM HU was then added into media for 4 hours at 37 °C. Cells were 330 pre-extracted for 5 minutes on ice with Pre-extraction buffer (20 mM NaCl, 3 mM MgCl2, 300 mM Sucrose, 10 mM 331 PIPES, 0.5 % Triton X-100) and fixed in 4 % PFA for 10 minutes before blocking in 3 % BSA for 16 hours. Blocking 332 media was removed and click it reaction cocktail (PBS, 10 μM Biotin Azide, 10 mM sodium ascorbate, 1 mM CuSO4) 333
was added for 1 hour at room temperature. Click it reaction was washed and cells blocked in 5 % BSA for 30 334 minutes. Cells were then incubated with primary antibodies, Biotin (Jackson Immunoresearch) and RAD51 335 (Calbiochem) in 3 % FCS in PBS for 1 hour at room temperature. After incubation with primary antibodies cells were 336 incubated with the MINUS/PLUS PLA probes (Sigma Duolink PLA kit) for 1 hour at 37 °C in a warm foil covered box. 337
Cells were then washed twice for 5 minutes with wash buffer A (Sigma Duolink PLA kit) and incubated with the 338
Sigma Duolink Ligation kit (1X ligation buffer, ligase enzyme) for 30 minutes at 37 °C. Cells were washed twice for 5 339 minutes with wash buffer A and incubated for 100 minutes at 37 °C with the Sigma Duolink amplification kit (1X 340 amplification buffer, polymerase enzyme). Finally they were washed twice for 10 minutes with wash buffer B at 341 room temperature and coverslips were mounted using the Duolink mounting media with DAPI (Sigma). 342
GST-PIN1 Pull down assay 343
Cells were washed with 10 ml ice cold PBS before being lysed in 5 ml TG lysis buffer (40 mM Tris-HCL pH 8, 274 mM 344
NaCl, 2 mM EGTA, 3 mM MgCl2, 2 % Triton x100, 20 % Glycerol) with addition of cOmplete protease inhibitor 345 cocktail (Roche) and PhosSTOP (Roche) tablets. The lysed cells were transferred into 1.5 ml Eppendorf tubes 346 incubated on ice for 20 mins and sonicated twice at 20 % intensity for 10 seconds. Samples were spun at 13000 rpm 347 at 4 °C for 10 mins and the supernatant kept. 50 μl of the supernatant was mixed with 20 μl 4x SDS Loading buffer 348 and boiled at 95 °C for 5 mins. 800 μl of the cell supernatant was then incubated with equal concentrations of GST-349 WW PIN1 and GST-W34A PIN1 beads for 2 hours at 4°C. The GST-pull downs were washed three times in TG lysis 350 buffer before adding 60 μl 4x SDS loading buffer directly to the beads. Samples were boiled at 95°C for 5 mins and 351 then 40 μl loaded onto an SDS PAGE gel and analyzed by western blotting. 352
Flag immunoprecipitation 353
Cells were plated in a 10 cm 2 plate and treated with Doxycycline for 48 hours to express inducible EGFP-Flag-BRCA1 354 or RFP-Flag-BARD1. Cells were washed with 10 ml ice cold PBS before being scraped in ice cold Nuclear Lysis Buffer 355 (10 mM HEPES pH7.6, 200 mM NaCl, 1.5 mM MgCl2, 10 % Glycerol, 0.2 mM EDTA, 1 % Triton) with addition of 356 cOmplete protease inhibitor cocktail (Roche) and PhosSTOP (Roche) tablets and 20 μM MG132 for every 10 ml. The 357 lysed cells were then transferred into 1.5 ml Eppendorf tubes incubated on ice for 10 mins, and sonicated 1 time at 358 20% intensity for 10 seconds. Samples were spun at 13000 rpm at 4°C for 10 mins and the supernatant kept, the 359 pellet was discarded. 50 μl of the supernatant was mixed with 20 μl 4x SDS Loading buffer and boiled at 95°C for 5 360 mins. For every IP, 10 μl Flag-agarose beads were firstly washed out of storage buffer by doing 3x 1ml PBS washes 361 and centrifuging at 3000 rpm between each wash. 90 μl of PBS was added for every 10 μl of agarose beads. Once 362 the beads were resuspended in PBS, 100 μl were transferred into an Eppendorf with 500 μl of supernatant and 500 363 μl of PBS. The Eppendorfs were rotated for 2 hours at 4°C. Samples were centrifuged at 3000 rpm for 1 min and the 364 beads left to settle. The supernatant was then removed before 3x 1 ml PBS-0.02% tween washes. The wash buffer 365 was completely removed before adding 60 μl 2x SDS loading buffer. This was boiled at 95°C for 5 mins and then 20 366 μl loaded onto an SDS PAGE gel and analysed by western blotting. 367 368 369 Fibre Labelling and spreading 370 Cells were seeded in 6 cm 2 plates at a density of 20x 10 4 cells/well and treated with thymidine analogues. To 371 monitor stability of nascent DNA cells were incubated at 37 °C with CldU for 20 mins at a final concentration of 25 372 μM and then with 5 mM HU for 3 hours. To monitor replication fork restart cells were incubated at 37 °C with CldU 373
for 20 mins at a final concentration of 25 μM and then with 5 mM HU for 3 hours. The HU was then washed out 374 with 3x PBS washes and cells were incubated for a further 40 mins in media containing 250 μM IdU at 37°C. After 375 incubation with thymidine analogues, cells were washed 2x with ice-cold PBS for 5 minutes with rotation then 376 trypsinised, resuspended in 1ml of PBS and counted. The optimal concentration is 50 x 10 4 cells/ml and thus cells 377
were adjusted to such concentration. 2 μl of the cell sample was placed on Snowcoat microscope slides and allowed 378 to slightly dry for 7 mins. Then 7 μl of spreading buffer (200 mM Tris pH7.4, 50 mM EDTA, 0.5% SDS) was mixed with 379 the sample and incubated for 2 mins to lyse the cells. In order to spread the sample down the slide, slides were 380 gradually tilted and once the sample had reached the bottom of the slide, they were allowed to dry for 2 mins. 381
Finally, slides were fixed in a 3:1 ratio of Methanol: Acetic acid for 10 mins before leaving slides to air dry for 5-10 382 mins. Dried slides were stored at 4°C till staining. 383
Fibre Immunostaining 384
After fibre spreading slides were washed twice for 5 minutes with 1 ml H2O and rinsed with 2.5 M HCl before 385 denaturing DNA with 2.5 M HCl for 1 hour 15 mins. Slides were then rinsed 2 x with PBS and washed for 5 minutes 386
in blocking solution (PBS, 1 % BSA, 0.1 % Tween20). Slides were incubated for 1 hour in blocking solution. After 387 blocking, each slide was incubated with 115 μl of primary antibodies, Rat αBrdU (AbD Serotec/Abcam) used at a 388 concentration of 1:2000 and Mouse αBrdU (Becton Dickinson) used at 1:750. Slides were covered with large 389 coverslips and incubated with the antibodies for 1 hour. After incubation with the primary antibody, slides were 390 rinsed 3x with PBS and then incubated for 1 min, 5 mins and 30 mins, with blocking solution. After rinsing and 391 washing, slides were incubated with 115μl of secondary antibodies (α-Rat AlexaFluor 555 and α-Mouse AlexaFluor 392 488) in blocking solution, at a concentration of 1:500, covered with a large coverslip for 2 hours. Slides were rinsed 393 3x with PBS and incubated with blocking solution for 1 min, 5 mins and 30 mins. After again rinsing 2 x with PBS, 394 immunomount mounting media was added to the slide and a large coverslip placed over and left to dry. Coverslips 395
were then stored at -20°C for microscopy analysis. It is important to point out that during this process slides must 396 be kept protected from light. 397
Immunofluorescent staining 398
U20S WT or S114A-BRCA1 cells were plated at a density of 5 x 10 4 cells/ml in 24 well plates on circular glass 399 coverslips (13 mm). Cells were treated siBRCA1 for 48 hours and complemented with WT or S114A BRCA1 by 400 addition of Doxycycline. Cells were then treated with 20 µM Olaparib for 2 hours. Cells were pre-permeablised by 401 incubation with 0.5 % Triton-PBS on ice for 10 minutes before fixation with 4 % PFA. Once fixed the cells were 402 permeabilised for a further 5 mins using 0.5 % TritonX in PBS before incubation with blocking solution -10% FCS in 403 PBS for 30 mins. Cells were then incubated with rabbit polyclonal RAD51 (H92) antibody in 10% FCS PBS at room 404 temperature overnight. The following day, cells were washed in PBS/FCS before incubating them with AlexaFluor-405 488 secondary antibody at a 1:2000 concentration, for 2 hours. Cells were then washed three times in PBS and the 406 DNA stained using Hoescht at a 1:20000 concentration for 5 mins. Excess of Hoescht was washed with PBS and 407 coverslips mounted onto Snowcoat slides using Immunomount mounting media. 408 409 410
EdU staining 411
Cells subjected to immunofluorescent staining were also subjected to EdU staining. Cells were incubated with 10 412 μM final concentration of EdU for 2 hours prior to fixing and staining was carried out as detailed in the Click-iT® EdU 413
Imaging Kits (Life Technologies). 414
CldU Immunostaining 415
Cells were plated at a density of 5 x 10 4 cells/ml in 24 well plates on circular glass coverslips (13 mm). Cells were 416 treated as described and incubated at 37 °C with CldU for 20 mins at a final concentration of 25 μM. Cells were then 417 fixed with 4 % PFA and permeabilised for 5 mins using 0.25 % TritonX in PBS. After permeabilisation, cells were 418
washed twice with PBS and twice with blocking solution containing 10 % FCS in PBS. 2 M HCl was added for 30 mins 419
at 37 °C and cells incubated with 10 % FCS in PBS for 1 hour at room temperature (RT). Cells were then incubated 420
with FLAG (M2-Sigma)(1:1000) and Rat αBrdU (AbD Serotec) (1:500), in 10 % FCS PBS at RT, for 1 hour. After 421 primary antibody incubation, cells were washed 3x in PBS and then incubated for 10 mins in stringency buffer (0.5 422 M NaCl, 36 mM Tris pH 7.5-8, 0.5 % Tween20), before incubating them with AlexaFluor antbodies at a 1:500 423 concentration, for 2 hours. Cells were then washed twice with PBS and once with stringency buffer, and DNA 424 stained using Hoescht at a 1:20000 concentration for 5 mins. Excess of Hoescht was washed with PBS and coverslips 425 mounted onto Snowcoat slides using Immunomount mounting media. 426
Microscopy 427
Immunofluorescent staining was imaged using the Leica DM6000B microscope using a HBO lamp with 100W 428 mercury short arc UV bulb light source and four filter cubes, A4, L5, N3 and Y5, which produce excitations at 429 wavelengths 360 488, 555 and 647 nm respectively. 430
Western blotting 431
Acrylamide SDS PAGE protein gels were run and then transferred onto PVDF Immobilon-P membrane, which was 432 previously activated with methanol. Transfers were set up in Biorad Trans-blot cassettes with a sponge and 2 pieces 433 of filter paper either side of the membrane and gel. The cassette was then placed in the tank with 1x Transfer buffer 434 20 % Methanol and ran at 100 volts for 1 hour. 435
After the transfer the membrane was blocked in 5 % marvel milk in PBS with 0.1 % Tween (PBStw) or in 5 % BSA 436
with PBStw, for a minimum of 1 hour. Membranes were then incubated in primary antibody (for a full list of 437 antibodies see Supplementary Table 2 ) accordingly at 4 °C on a roller. Blots were then washed 3x 10 mins in PBStw 438 and then transferred into secondary HRP antibodies in 5 % marvel milk for a minimum of 1 hour whilst being 439 rocked. After secondary incubation, blots were again washed 3x 10 mins in PBStw. Finally membranes were probed 440 with 1:1 EZ-ECL mix (Biological Industries), the excess of ECL was removed and the membrane was placed into a 441 plastic wallet that was placed inside a cassette. A Fuji film X-Ray film was placed in the cassette for differential 442 length of time and then it was developed using the Xograph Compact X4 developer. Densitometry calculations were 443 performed using Image J. 444 p-S114 Antibody Generation 445
Custom mouse monoclonal and rabbit polyclonal antibodies were raised against BRCA1 phospho-S114 by Genscript 446 using the following peptide: CFAKKENNpSPEHLKD 447 448 BRCA1:BARD1 protein expression and purification 449
WT and P115A His-BRCA11-500 -BARD127-327 for in vitro analysis The expression of His-BRCA1-WT + BARD1-WT and 450
His-BRCA1-PA + BARD1-WT in Rosetta™(DE3) was induced by the addition of 1 mM Isopropyl-β-d-451 thiogalactopyranoside (IPTG), and the proteins were produced in LB medium containing 50 μg/ml of kanamycin, 100 452 μg/ml of ampicillin and 30 μg/ml of chloramphenicol at 37°C for 5 hours. For purification of the His-BRCA1-WT + 453 BARD1-WT and His-BRCA1-PA + BARD1-WT products, the cells were harvested and resuspended in 20 mM HEPES 454 potassium salt, pH 7.4, 50 mM Imidazole, 500 mM NaCl, 1.0 mM TCEP [tris(2-carboxyethyl)phosphine], cOmplete 455
EDTA-free protease inhibitor cocktail tablet (Roche). Cells were lysed using an Emulsiflex-C3 homogenizer (Avestin) 456
and broken by three passages through the chilled cell. The lysate was centrifuged at 75,000 xg using a JA 25.50 rotor 457 (Beckman Coulter) and filtered through a 0.45-μm filter. The clarified lysate was applied onto a 5-ml HisTrap HP 458 column (GE Healthcare). The column was washed extensively using the same buffer, and the protein was eluted 459 using buffer containing 500 mM imidazole. 460
Fractions containing a band of the correct size were concentrated using a Vivaspin 20-ml concentrator (10,000 461 molecular weight cut-off [MWCO]) (GE Healthcare) and gel purified using an Akta Pure 25 (GE Healthcare LS) with a 462
prepacked Hi-Load 10/300 Superdex 200 PG column. 463
WT and S114A BRCA11-300 for CDK2 kinase assay. BRCA1 and BARD1 proteins were expressed from pET15b-His-464 BRCA11-300:His-BARD126-142 vector in BL21(DE3) bacteria (Bioline). Bacteria were grown at 37 °C until an optical 465 density of 0.6 was reached. Protein expression was induced by addition of 0.5 mM isopropyl β-D-1-466 thiogalactopyranoside (IPTG) (Bioline), and the temperature was immediately decreased to 25 °C. Bacteria were 467 grown for a further 24 h. Bacterial pellets were collected after centrifugation at 3,000g for 10 min at 4 °C and then 468 lysed in ice-cold lysis buffer (50 mM sodium phosphate, pH 7, 300 mM sodium chloride, 5% glycerol and 10 mM β-469 mercaptoethanol). Lysates were sonicated for 1 min at 30 % intensity and then clarified by centrifugation at 14000g 470 for 10 min at 4 °C. The supernatant was incubated with 0.25 ml His-select beads (Sigma) overnight at 4 °C with 471 rotation. The following day, the beads were washed three times with ice-cold wash buffer (50 mM sodium 472 phosphate, pH 7, 300 mM sodium chloride, 5 % glycerol, 10 mM β-mercaptoethanol and 50 mM imidazole) before 473 elution on ice in 50 mM sodium phosphate, pH 7, 300 mM sodium chloride, 5 % glycerol, 10 mM β-mercaptoethanol 474 and 300 mM imidazole. Purified proteins were dialyzed against (25 mM Tris-HCl, pH 7.5, 10 % glycerol, 2 mM 475 dithiothreitol (DTT) and 150 mM potassium chloride), and purity was assessed by resolution on a 15 % SDS-PAGE 476 gel. 477 RAD51 in vitro binding assay 478 0.5 μl of Human recombinant RAD51 (Abcam) was incubated with 40 μl of a 50% slurry of His-BRCA1-WT + BARD1-479
WT or His-BRCA1-PA + BARD1-WT immobilized in Ni 2+ -resin together with 500 μl of RAD51 binding buffer (25 mM 480
Tris-HCl pH 7.5, 10% Glycerol, 0.5 mM EDTA, 0.05% Igepal CA-630, 1mM 2-mercaptoethanol, 150 mM KCl, 50mM 481
Imidazole) for 30 minutes at 4°C in rotation. After incubation the resin was washed three times with the RAD51 482 binding buffer before eluting in 40 μl 4x SDS loading buffer at 95°C for 5 minutes. The SDS elute was then analyzed 483
by Western blotting and Coomassie blue staining. 484
Trypsin proteolytic digestion 485
The His-BRCA11-500-BARD127-327 fragment was subjected to trypsin proteolytic digestion and 50 μl of the His-BRCA1-486 WT + BARD1-WT or the His-BRCA1-PA + BARD1-WT (0.5 mg/ml) was incubated with 50 μl of the Trypsin digestion 487 buffer (25 mM Tris pH 7.5, 10 % Glycerol, 2 mM DTT and 150 mM KCl) and 2 μl of trypsin (20 ng/μl). Once trypsin 488 was added, samples were immediately incubated at 37 °C and time points collected after 3, 7, 15, 30, 60 and 90 489 minutes and eluted in 4x SDS-PAGE loading buffer. Samples were boiled at 95°C for 5 mins and then 5 μl loaded 490 onto an SDS PAGE gel and analyzed by western blotting using the MS110 BRCA1 antibody. 491 CDK2-Cyclin A Kinase assay 492 50 ng of WT or S114A His-BRCA11-300:His-BARD126-142 were incubated with 50ng of recombinant CDK2-Cyclin A 493 (Sigma C0495) in 25 mM MOPS pH7.2, 12.5 mM -glycerolphosphosphate, 25 mM magnesium chloride, 5mM EGTA, 494 2 mM EDTA, 0.5 mM DTT and 50 ng/µl BSA. The kinase reaction was started by addition of 10 mM ATP and samples 495
were incubated at 30 o C for 30 minutes. The reaction was stopped by addition of 4x SDS-PAGE loading buffer and 496 incubated at 95 o C for 5 minutes. 5 µl of the total reaction was run on 14 % SDS PAGE gel before transfer to 497
Immobilon-P membrane (MERCK-Millipore) and western blotting for phospho-S114 (3C10G8) or BRCA1 (MS110). 498
Recombinant PIN1 protein expression 499
Bl21 Escherichia Coli were transformed with the pGEX protein expression vector containing the protein of interest. 500
Colonies were picked and grown up in 50 ml starter cultures containing Ampicillin at 37°C for 16 hours at 200 rpm. 501
Starter cultures were transferred to 500 ml Luria Bertani (LB) containing Amp and grown for 2 hours at 37 °C at 200 502 rpm. Bacterial expression was induced using 0.5 mM IPTG and bacteria left to grow for 5 hours at 37°C at 200 rpm. 503
Recombinant PIN1 Protein purification 504
Bacteria were pelleted by centrifuging at 12000 rpm for 10 mins at 4°C. Then the bacterial pellet was lysed in 10 ml 505
GST lysis buffer (20 mM Tris-HCL pH8, 130 mM NaCl, 1 mM EGTA, 1.5 mM MgCl2, 1 % Tritonx-100, 10 % Glycerol, 1 506 mM DTT) with 1 protease inhibitor tablet (Roche). Bacteria were resuspended and left on ice for 20 mins and then 507 sonicated 2 times at 20% intensity for 10 seconds. Lysed bacteria were spun 20 mins at 13000 rpm to pellet debris. 508
Supernatant was transferred to a 50 ml falcon tube and made up to 35 ml with lysis buffer and 500 μl of pre-washed 509
Glutathione Sepharose 4B beads (GE Life Sciences) and rotated at 4°C for 16 hours. 510
Site-Directed Mutagenesis 511
Specific primers were designed for mutagenesis ( Supplementary Table 3 ) and mutagenesis performed by PCR using 512
PfU (Promega). All mutagenesis was confirmed by Sanger Sequencing (Source Bioscience). 513
Statistics 514
All statistics were done using two-sided Student's T-test. Significance is defined as * p<0.05, **p<0.01 and 515 ***p<0.005 throughout. 516 GCTGTTTGCATTCTCCAAACCTGTGTC S114A_F GGAAAATAACGCTCCTGAACATC S114A_R GATGTTCAGGAGCGTTATTTTCC S114D_F GGAAAATAACGACCCTGAACATC S114D_R GATGTTCAGGGTCGTTATTTTCC S114P_F GGAAAATAACCCTCCTGAACATC S114P_R GATGTTCAGGAGGGTTATTTTCC P115A_F GGAAAATAACTCTGCTGAACATCTAAAAG P115A_R CTTTTAGATGTTCAGCAGAGTTATTTTCC S114AP115A_F GGAAAATAACGCAGCAGAACATC S114AP115A_R GATGTTCTGCTGCGTTATTTTCC S114AP115C_F GGAAAATAACGCTTGTGAACATCTAAAAG S114AP115C_R CTTTTAGATGTTCACAAGCGTTATTTTCC  Y179C_F  GACGTCTGTCTGCATTGAATTGGGATC  Y179C_R  GATCCCAATTCAATGCAGACAGACGTC  S184C_F  CATTGAATTGGGATGTGATTCTTCTGAAG  S184C_R  CTTCAGAAGAATCACATCCCAATTCAATG  S265Y_F  GTATCAGGGTAGTTATGTTTCAAACTTGC  S265Y_R  GCAAGTTTGAAACATAACTACCCTGATAC  M1411T_F  CTCCAGCAGGAAACGGCTGAACTAGAAGC  M1411T_R  GCTTCTAGTTCAGCCGTTTCCTGCTGGAG   BARD1   AAE_F  CCTAGGAAAAGTTTGGCTAATGCTGAAGGAAACAAGAAGAATTC  AAE_R  GAATTCTTCTTGTTTCCTTCAGCATTAGCCAAACTTTTCCTAGG  D135Y_F  CAGATTTGAAAGAATATAAACCTAGGAAAAG  D135Y_R  CTTTTCCTAGGTTTATATTCTTTCAAATCTG  K144N_F  GAAGAATTCAATTAACATGTGGTTTTCGC  K144N_R  GCGAAAACCACATGTTAATTGAATTCTTC  F147C_F  CAATTAAAATGTGGTGTTCGCCACGTAGTAAG  F147C_R CTTACTACGTGGCGAACACCACATTTTAATTG S148A_F CAATTAAAATGTGGTTTGCGCCACGTAGTAAG S148A_R CTTACTACGTGGCGCAAACCACATTTTAATTG S148D_F CAATTAAAATGTGGTTTGACCCACGTAGTAAG S148D_R CTTACTACGTGGGTCAAACCACATTTTAATTG S162A_F GTTGTGAGTAAAGCTGCAGTGCAAACCCAG S162A_R 
